- Home
- WHLR vs GLTO Comparison
WHLR vs GLTO Comparison
Compare WHLR & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHLR
- GLTO
- Stock Information
- Founded
- WHLR 2011
- GLTO 2011
- Country
- WHLR United States
- GLTO Denmark
- Employees
- WHLR N/A
- GLTO N/A
- Industry
- WHLR Real Estate Investment Trusts
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- WHLR Real Estate
- GLTO Health Care
- Exchange
- WHLR Nasdaq
- GLTO Nasdaq
- Market Cap
- WHLR 1.5M
- GLTO 4.5M
- IPO Year
- WHLR 2012
- GLTO 2020
- Fundamental
- Price
- WHLR $5.81
- GLTO $3.54
- Analyst Decision
- WHLR
- GLTO Buy
- Analyst Count
- WHLR 0
- GLTO 1
- Target Price
- WHLR N/A
- GLTO $10.00
- AVG Volume (30 Days)
- WHLR 2.9M
- GLTO 13.7K
- Earning Date
- WHLR 08-05-2025
- GLTO 08-11-2025
- Dividend Yield
- WHLR N/A
- GLTO N/A
- EPS Growth
- WHLR N/A
- GLTO N/A
- EPS
- WHLR N/A
- GLTO N/A
- Revenue
- WHLR $102,793,000.00
- GLTO N/A
- Revenue This Year
- WHLR N/A
- GLTO N/A
- Revenue Next Year
- WHLR N/A
- GLTO N/A
- P/E Ratio
- WHLR N/A
- GLTO N/A
- Revenue Growth
- WHLR 0.86
- GLTO N/A
- 52 Week Low
- WHLR $3.33
- GLTO $2.01
- 52 Week High
- WHLR $12,574.80
- GLTO $16.07
- Technical
- Relative Strength Index (RSI)
- WHLR 48.32
- GLTO 59.96
- Support Level
- WHLR $5.65
- GLTO $3.24
- Resistance Level
- WHLR $6.40
- GLTO $3.60
- Average True Range (ATR)
- WHLR 0.93
- GLTO 0.26
- MACD
- WHLR 0.21
- GLTO -0.01
- Stochastic Oscillator
- WHLR 11.09
- GLTO 60.98
About WHLR Wheeler Real Estate Investment Trust Inc.
Wheeler Real Estate Investment Trust Inc is a self-managed commercial real estate investment company. It owns, leases, and operates income-producing retail properties with a primary focus on grocery-anchored centers. The company's properties include Alex City Marketplace in Alexander City, Alabama; Bryan Station in Lexington, Kentucky; Cardinal Plaza in Henderson, North Carolina; Clover Plaza in Clover, South Carolina; Winslow Plaza in Sicklerville, New Jersey and many more.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.